Ubiquinol clinical brief
Ubiquinol
Dossier liveAmitochondrial_cofactor - strongest use in mitochondrial_dysfunction
Evidence strength
High confidence
19 meta-analyses - 110 RCTs - 186 tracked studies
This page is grounded in structured dossier fields, with deterministic summaries layered on top for readability.
What it is for
Heart failure adjunctive therapy (NYHA II-IV)
The clearest current human use case based on dose, outcomes, and clinical coverage.
What moves
Highest-signal biomarkers
Coq10 Plasma
Clinical response
Increase
Grade A
AST
Hepatic and liver
Decrease
Grade A
MMA
Methylation
Decrease
Grade A
Top caution
Drug interaction
Ubiquinol shares a naphthoquinone ring system structurally analogous to vitamin K; theoretical competition with vitamin K-dependent coagulation factor activation (factors II, VII, IX, X); may reduce anticoagulant efficacy in some patients; effect is inconsistent across case reports
Evidence index
87
Promoted product-registry confidence score
Meta-analyses
19
Pooled human evidence
RCTs
110
Randomized clinical trials
Tracked studies
186
Studies currently mapped to this dossier
Preview summary
Clinical opening brief
This executive summary is generated by application logic from structured dossier evidence and safety fields.
Ubiquinol is a mitochondrial_cofactor sourced from endogenous_biosynthesis_and_dietary with its clearest current use in Heart failure adjunctive therapy (NYHA II-IV).
High confidence human evidence supports the brief, anchored by 186 tracked studies, 19 meta-analyses, 110 RCTs and the most reliable movement in Coq10 Plasma, AST, MMA.
Ubiquinol shares a naphthoquinone ring system structurally analogous to vitamin K; theoretical competition with vitamin K-dependent coagulation factor activation (factors II, VII, IX, X); may reduce anticoagulant efficacy in some patients; effect is inconsistent across case reports Ubiquinol shares a naphthoquinone ring system structurally analogous to vitamin K; theoretical competition with vitamin K-dependent coagulation factor activation (factors II, VII, IX, X); may reduce anticoagulant efficacy in some patients; effect is inconsistent across case reports Anti-inflammatory claims most valid for chronic cardiovascular, metabolic, and autoimmune disease; do not extrapolate to acute critical illness, burns, or sepsis based on current evidence
Research unlocks the working sections of the brief
The clinical opening stays public. Research opens the deeper evidence, biomarker, dosing, and PGx layers once you want the full operating brief.
Evidence, biomarkers, dosing, and PGx stay behind the glass
You are already inside the dossier. Upgrade when you need the full working sections instead of only the opening memo.